Correlation Between Structure Therapeutics and Inozyme Pharma

Can any of the company-specific risk be diversified away by investing in both Structure Therapeutics and Inozyme Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Structure Therapeutics and Inozyme Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Structure Therapeutics American and Inozyme Pharma, you can compare the effects of market volatilities on Structure Therapeutics and Inozyme Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Structure Therapeutics with a short position of Inozyme Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Structure Therapeutics and Inozyme Pharma.

Diversification Opportunities for Structure Therapeutics and Inozyme Pharma

-0.03

Correlation Coefficient

Structure Therapeutics  Inozyme Pharma

Good diversification

The 3 months correlation between Structure and Inozyme is -0.03. Overlapping area represents the amount of risk that can be diversified away by holding Structure Therapeutics America and Inozyme Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Inozyme Pharma and Structure Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Structure Therapeutics American are associated (or correlated) with Inozyme Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Inozyme Pharma has no effect on the direction of Structure Therapeutics i.e., Structure Therapeutics and Inozyme Pharma go up and down completely randomly.

Pair Corralation between Structure Therapeutics and Inozyme Pharma

Given the investment horizon of 90 days Structure Therapeutics American is expected to under-perform the Inozyme Pharma. But the stock apears to be less risky and, when comparing its historical volatility, Structure Therapeutics American is 10.79 times less risky than Inozyme Pharma. The stock trades about -0.14 of its potential returns per unit of risk. The Inozyme Pharma is currently generating about 0.18 of returns per unit of risk over similar time horizon. If you would invest  142.00  in Inozyme Pharma on May 15, 2025 and sell it today you would earn a total of  258.00  from holding Inozyme Pharma or generate 181.69% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	54.1%
Values	Daily Returns

Structure Therapeutics America  vs.  Inozyme Pharma

Structure Therapeutics

Risk-Adjusted Performance

Weakest

Over the last 90 days Structure Therapeutics American has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unfluctuating performance in the last few months, the Stock's fundamental indicators remain relatively invariable which may send shares a bit higher in September 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Inozyme Pharma

Risk-Adjusted Performance

Good

Over the last 90 days Inozyme Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly unfluctuating basic indicators, Inozyme Pharma showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Structure Therapeutics and Inozyme Pharma

The main advantage of trading using opposite Structure Therapeutics and Inozyme Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Structure Therapeutics position performs unexpectedly, Inozyme Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inozyme Pharma will offset losses from the drop in Inozyme Pharma's long position.

The idea behind Structure Therapeutics American and Inozyme Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.